Tyra Biosciences (NASDAQ:TYRA) Stock Price Down 7.3%

Tyra Biosciences, Inc. (NASDAQ:TYRA)’s share price traded down 7.3% during mid-day trading on Thursday . The company traded as low as $14.79 and last traded at $14.84. 34,082 shares traded hands during mid-day trading, a decline of 74% from the average session volume of 129,525 shares. The stock had previously closed at $16.00.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Wedbush reaffirmed an “outperform” rating and issued a $28.00 price objective on shares of Tyra Biosciences in a research report on Thursday, March 21st. HC Wainwright reaffirmed a “buy” rating and issued a $23.00 price objective (up previously from $19.00) on shares of Tyra Biosciences in a research report on Wednesday, March 20th.

Tyra Biosciences Trading Down 5.6 %

The company has a market cap of $793.58 million, a PE ratio of -9.29 and a beta of 1.12. The firm’s 50-day simple moving average is $17.53 and its two-hundred day simple moving average is $14.84.

Tyra Biosciences (NASDAQ:TYRA) last released its earnings results on Tuesday, March 19th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.05). As a group, analysts predict that Tyra Biosciences, Inc. will post -1.89 EPS for the current year.

Insiders Place Their Bets

In other news, COO Daniel Bensen sold 1,733 shares of the company’s stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $20.09, for a total value of $34,815.97. Following the sale, the chief operating officer now directly owns 431,951 shares of the company’s stock, valued at approximately $8,677,895.59. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last quarter, insiders have sold 15,816 shares of company stock valued at $298,165. Insiders own 18.40% of the company’s stock.

Institutional Trading of Tyra Biosciences

Large investors have recently made changes to their positions in the business. Simplex Trading LLC boosted its holdings in shares of Tyra Biosciences by 198.1% in the 3rd quarter. Simplex Trading LLC now owns 2,009 shares of the company’s stock valued at $27,000 after acquiring an additional 1,335 shares during the last quarter. Federated Hermes Inc. lifted its stake in shares of Tyra Biosciences by 1,244.2% in the 4th quarter. Federated Hermes Inc. now owns 2,070 shares of the company’s stock valued at $29,000 after purchasing an additional 1,916 shares during the period. AJOVista LLC acquired a new position in shares of Tyra Biosciences in the 4th quarter valued at $59,000. Exchange Traded Concepts LLC lifted its stake in shares of Tyra Biosciences by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 9,531 shares of the company’s stock valued at $132,000 after purchasing an additional 2,417 shares during the period. Finally, Corton Capital Inc. acquired a new position in shares of Tyra Biosciences in the 3rd quarter valued at $152,000. 84.14% of the stock is owned by hedge funds and other institutional investors.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.